Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
“Patients with stage IB-IIIA or IIB disease should be considered for neoadjuvant and/or adjuvant systemic therapy based on biomarker testing for PD-L1 status, EGFR mutations, and ALK gene fusions.” — NCCN NSCLC Guidelines, Version 3, 2026
Medical Oncology February 17th 2026
Journal of Invasive Cardiology (JIC)
This “olive sign” indicates subvalvular stent compression, resulting in valve instability and potential migration into the ascending aorta.
Cardiology, Interventional October 22nd 2025
Lung Cancers Today
Global phase 3 study randomized patients with platinum-refractory extensive-stage SCLC to first-in-class bispecific immunotherapy versus regional standard chemotherapy, achieving primary overall survival endpoint with consistent safety profile.
Medical Oncology June 24th 2025
Northwestern Medicine
The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.
Medical Oncology December 3rd 2024
ACP Internist
A 75-year-old man with dyspnea and exertional syncope is diagnosed with aortic stenosis. After an echocardiogram, what’s next?
Cardiology November 8th 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS